BioPharmSignal logoBioPharmSignal

Biotech News

Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results

Pulmatrix (PULM)PulmatrixEarnings

PULM (PULM) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is pulm.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

PULMPulmatrix2026-08-13 12:15 EST

Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger

PULMPulmatrix2026-05-15 12:20 EST

Pulmatrix Announces First Quarter 2026 Financial Results

XAIRBeyond Air2026-06-26 11:00 EST

Beyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update

TBPHTheravance Biopharma2026-03-19 12:30 EST

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

LUNGPulmonx2026-03-04 21:06 EST

Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results

LUNGPulmonx2026-02-20 13:00 EST

Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

XAIRBeyond Air2026-08-13 11:00 EST

Beyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update

RVPHReviva Pharmaceuticals2026-08-12 20:29 EST

Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights

TBPHTheravance Biopharma2026-08-10 12:30 EST

Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

INSMInsmed2026-08-06 11:00 EST

Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update

View all latest news

Pulmatrix

Inhaled Drug-Delivery Company Pulmatrix developed inhaled therapies using its proprietary iSPERSE dry-powder technology. The company is seeking partners or other monetization routes for its legacy clinical assets while pursuing a merger with Eos SENOLYTIX. iSPERSE Technology iSPERSE creates small, dense, dispersible particles intended to...

Recent company news

PULMPulmatrix2026-08-13 12:15 EST

Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger

PULMPulmatrix2026-05-15 12:20 EST

Pulmatrix Announces First Quarter 2026 Financial Results

PULMPulmatrix2026-04-21 12:00 EST

Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger

PULMPulmatrix2026-03-26 12:00 EST

Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan

PULMPulmatrix2026-03-02 13:00 EST

Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities

Stock data

Close
1.56 USD
Market cap
4.82M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States